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Background & objectives: To develop a broad strain coverage GAS vaccine, several strategies have been
investigated which included multi-epitope approaches as well as targeting the M protein conserved C-
region. These approaches, however, have relied on the use of adjuvants that are toxic for human
application. The development of safe and effective adjuvants for human use is a key issue in the
development of effective vaccines. In this study, we investigated the lipid polylysine core peptide (LCP)
system as a self-adjuvanting GAS vaccine delivery approach.
Methods: An LCP-GAS construct was synthesised incorporating multiple copies of a protective peptide
epitope (J8) from the conserved carboxy terminal C-repeat region of the M protein. B10.BR mice were
immunized parenterally with the LCP-J8 construct, with or without conventional adjuvant, prior to
the assessment of immunogenicity and the induction of serum opsonic antibodies.
Results: Our data demonstrated immunogenicity of LCP-J8 when coadministered in complete Freund’s
adjuvant (CFA), or administered in the absence of conventional adjuvant. In both cases, immunization
led to the induction of high-titre J8 peptide-specific serum IgG antibody responses, and the induction
of heterologous opsonic antibodies that did not cross-react with human heart tissue proteins.
Interpretation & conclusion: These data indicated the potential of a novel self-adjuvanting LCP vaccine
delivery system incorporating a synthetic GAS M protein C-region peptide immunogen in the induction
of broadly protective immune responses, and pointed to the potential application of this system in
human vaccine development against infectious diseases.
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The development of a vaccine against group A
streptococci (GAS) the etiologic agents of rheumatic
fever and rheumatic heart disease has focused largely
on the bacterial surface anti-phagocytic M protein1,2.
The M protein is a major virulence factor in GAS infection
and consists of a variable amino terminal region which
defines the GAS serotype (over 100 serotypes are
known), and a highly conserved carboxy terminal C-
repeat region1.  Protective immunity to GAS infection
has been associated with type-specific opsonic antibodies
against M protein1, 2 although opsonic antibodies specific
to the C-region have been demonstrated in humans3, and
mice immunized with C-region peptides4, and are also
important in eliciting protective immunity to GAS5.  The
variability in M proteins and the potential for the induction
of autoimmunity due to antigenic molecular mimicry
between GAS M protein and heart antigens6-9, represent
significant hurdles in the development of a broad strain
coverage vaccine. Multivalent M protein constructs
containing epitopes from several type-specific regions
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of different M proteins5, 10, 11 and those based on the
conserved C-region5,12-14, have shown promising results
in animal trials. The efficacy of the GAS vaccine
constructs, however, required the use of adjuvants that
are not suitable for use in humans due to their toxicity.
The development of novel synthetic adjuvants offers the
possibility of vaccine delivery without the need for
additional, toxic, adjuvant.
Synthetic lipid-based compounds provide an attractive
alternative for vaccine delivery. Lipopeptide compounds
utilising a synthetic analog of the N-terminal moiety of
bacterial lipoprotein from Escherichia coli (tripalmitoyl-
S-glyceryl cysteine, Pam3cys) as a lipidic anchor
moiety15, were found to be potent immunogens with self-
adjuvanting properties, eliciting humoral and cellular
responses irrespective of the route of administration16-19.
The lipidic polylysine core peptide (LCP) system20, has
also been described using a lipidic anchor moiety in
conjunction with the multiple antigenic peptide system21,
and is uniquely designed to incorporate antigen, carrier
and adjuvant in a single molecular entity. Furthermore,
lipopeptide compounds represent potentially safe vaccines
for human application22.  LCP-based vaccine candidates
incorporating variable domains of Chlamydia
trachomatis outer membrane protein have been shown
to significantly enhance peptide immunogenicity when
compared to peptide monomers given alone in adjuvant23,
and an LCP compound incorporating a foot-and-mouth
disease viral peptide was immunogenic resulting in the
induction of anti-peptide antibodies in the absence of
additional adjuvant24.
This study was carried out to investigate the LCP
system as a novel self-adjuvanting GAS vaccine delivery
approach. An LCP construct was synthesised
incorporating multiple copies of a GAS M protein
conserved C-region protective conformational peptide
epitope, referred to as J8, which lacks potentially
deleterious T-cell autoepitopes25.  Mice were immunized
parenterally with the LCP-J8 construct prior to the
assessment of immunogenicity and the induction of serum
opsonic antibodies.
Material & Methods
Synthesis and purification of group A streptococcal
J8 peptide: The sequence of the J8 peptide is
QAEDKVKQSREAKKQVEKALKQLEDKVQ
corresponding to amino acid residues 344-355 inclusive
of the conserved carboxy terminal C-region of the M
protein of the M1 GAS strain. The J8 peptide used is a
chimeric peptide that contains 12 amino acids from the
M protein C-region (shown in bold) and is flanked by
yeast-derived GCN4 sequences which was necessary
to maintain the correct helical folding and conformational
structure of the peptide26.  J8 peptide was synthesised
by manual solid phase peptide synthesis using Boc (tert-
butoxycarbonyl) chemistry27, and peptide purification was
carried out on a Waters HPLC system (model 600
controller, 490 E UV detector, 60 F pump).
Synthesis of LCP-J8 construct: Boc (tert-
butoxycarbonyl)-L-amino acids and 4-
methylbenzhydrylamine (MBHA) resin (Novabiochem,
Läufelfingen, Switzerland) were used to synthesise the
LCP-J8 construct (Fig. 1). Racemic lipoamino acids
were synthesized with Boc protection according to
Gibbons et al28. For the synthesis of the LCP-J8
construct containing four copies each of J8 GAS peptide,
preactivated Boc-Gly-OH was coupled to the MBHA
resin. The next two cycles were carried out with Boc-
lipoamino acids containing 12 carbon atoms (C12: -HN-
CH[(CH2)9CH3]-OH) which was followed sequentially
by the coupling of Boc-Gly-OH, Boc-C12-OH and Boc-
Lys(Boc)-OH. After deprotection of the lysine a- and
e- amino groups, a four-branch system was formed by
coupling of Boc-Lys(Boc)-OH to the free amino groups.
After deprotection, four identical peptide J8 sequences
were synthesised directly onto each of the a- and e-
amino groups of each lysine of the branched lysine core
with the appropriate protecting groups applied on the
side chains of the amino acids. Thus, the lipophilic anchor
of the LCP-J8 construct contained three 2-amino-
dodecanoic lipoamino acids attached to the polylysine
core, with glycine spacers employed; one between the
resin and the first lipoamino acid and another between
the second and third lipoamino acids. Sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel electrophoresis resulted in a band for LCP-
J8 of the expected size. Determination of the mass
spectrum of LCP-J8 resulted in a calculated molecular
weight of 14,158.45 daltons.
Mice and immunization: All protocols were approved
by the Bancroft Centre Research Ethics Committee, and
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were carried out according to Australian National Health
and Medical Research guidelines for the care and use
of laboratory animals. Female (4-6 wk old) B10.BR mice
(Animal Resource Centre, Perth, WA, Australia) were
used (n=10 per group) in two separate experiments for
subcutaneous immunization at the tail base on day 0 with
30 µg LCP-J8, either emulsified 1:1 with complete
Freund’s adjuvant (CFA)  (Sigma, USA)  (LCP-J8/CFA),
or given alone in a total volume of 50 µl sterile-filtered
PBS (LCP-J8/PBS). After three weeks, mice received
a further four (exp 1) or five boosts (exp 2) at weekly
intervals with 3 µg LCP-J8/PBS prior to the collection
of blood. Controls received either 30 µg J8 GAS peptide
or pepM1 (amino terminal half of M protein) in CFA
with boosts of 3 µg in PBS, or CFA/PBS alone.
Collection of sera: Blood was collected one week after
the last immunization from each mouse by the tail artery
and allowed to clot at 37oC for 1 h followed by the
removal of clots by centrifugation at 3000 rpm for 10
min. Sera were then stored at -20oC.
ELISA: Enzyme-linked immunosorbent assay (ELISA)
was performed for the measurement of total IgG antibody
titres in sera, essentially as previously described4.  Serum
samples were assayed using two-fold dilutions of a 1 in
100 dilution of sera. For IgG isotyping, horse radish
peroxidase-conjugated sheep anti-mouse IgG1, IgG2a,
IgG2b and IgG3 antibodies (The Binding Site,
Birmingham, UK) were used as the secondary
antibodies. Antibody titres were defined as the lowest
dilution that gave an optical density (OD) reading at 450
nm of more than three standard deviations above the
mean OD of control wells containing normal mouse sera
(obtained from mice immunized with CFA in PBS).
Bactericidal assay : Serum opsonic antibodies against
the M1, 8830, NS27 and BSB24 GAS strains were
detected using an indirect bactericidal assay, as previously
described3, 4. Briefly, GAS were incubated end-over-end
at 37oC for 3 h in the presence of non-opsonic human
donor blood and either heat-inactivated (60oC for 10 min)
mouse immune or control normal mouse sera. GAS were
then plated in duplicate on 2 per cent (v/v) horse blood
agar plates and colonies counted after 24 h of incubation.
The percentage of GAS opsonized was determined by
counting the number of colonies growing after incubation
with test immune sera and comparing this with the
number of colonies growing after incubation with control
sera. The opsonic activity (% reduction in mean cfu)
was calculated as [1-(cfu in the presence of immune
sera)/(mean cfu in the presence of normal mouse sera)]x
100.
Peptide inhibition bactericidal assay : Peptide
inhibition bactericidal assay was performed essentially
as described above except that sera were initially
incubated for 30 min at room temperature with 100 µg
peptide, or no peptide, prior to incubation with GAS and
non-opsonic donor blood. Peptides used were J8 GAS
peptide, and a non-specific control peptide from
Schistosoma (EGKVSTLPLDIQIIAATMSK). The
percentage inhibition of opsonisation was calculated as
(immune sera with peptide cfu-immune sera with no
peptide cfu/normal mouse sera with no peptide cfu-
immune sera with no peptide cfu) x 100.
Western blot analysis: Mouse LCP-J8 antisera were
tested for cross-reactivity to four different human heart
preparations (two heart and two mitral valve extracts)
obtained from patients undergoing heart transplant
surgery at The Prince Charles Hospital with ethical
approval from The Prince Charles Hospital Foundation,
porcine heart myosin (Sigma, USA) and porcine muscle
tropomyosin (Sigma), using standard SDS-PAGE and
Western blot analysis4. The J8 GAS peptide was
conjugated to diptheria toxoid (DT) and included as a
positive control. Pre-stained kaleidoscope protein size
markers were used (Biorad, Hercules, CA, USA).
Antiserum was used as the primary antibody at a dilution
of 1: 1,500 and the secondary sheep anti-mouse IgG
antibody (Silenus Pty Ltd., Melbourne, VIC, Australia)
was used at a dilution of 1: 1,500.
Statistical analysis: Analysis of variance (ANOVA)
with Tukey’s post-hoc method for multiple comparisons
was used for the comparison of antibody titres and
percentage opsonisation levels between the different
groups. SPSS Release 10.0 was used for statistical
analysis. P <0.05 was taken as statistically significant.
Results
Serum IgG antibody response in B10.BR mice
immunized with LCP-J8 : In the first experiment
(Fig. 2A), in which mice received a primary immunization
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and four boosts each of the same immunogen, J8-specific
antibodies were detected in all mice three weeks after
the primary immunization with LCP-J8 in CFA, and J8
in CFA giving a final average antibody titre after four
boosts of 1.5 x 106 and 1.4 x 105, respectively (exp 1;
Fig.2A). J8-specific antibodies were not detected at three
weeks post-immunization, in mice immunized with LCP-
J8 without adjuvant. However, after one boost of
immunogen, six of the nine mice had J8-specific
antibodies and after the third boost, antibodies to J8 were
detected in all mice. After the final boost (boost number
four) the average J8 antibody titre in mice immunized
with the LCP construct without adjuvant was 4.4 x 104
(exp 1). In the second experiment (Fig.2B), in which
mice received a primary immunization and five boosts
each of the same immunogen, the final average J8-
specific serum IgG antibody titres were approximately
1.3 x 106, 5.0 x 104 and 7.5 x 105 for mice immunized
with LCP-J8/CFA, LCP-J8/PBS and J8/CFA,
respectively. IgG isotyping demonstrated strong J8-
specific IgG1, IgG2b and IgG2a antibody responses with
lower titres or no J8-specific antibodies detected for IgG3
in LCP-J8/CFA and J8/CFA-immunized mice. In mice
immunized with LCP-J8 alone, there was a strong IgG1
response and IgG3 was only detected in one mouse. Of
these mice, 50 per cent demonstrated an IgG2a response
(exp 2) and IgG2b was barely detected in either
experiment. No IgG2a was detected in experiment 1.
Our data showed that the LCP-J8 construct was more
immunogenic in CFA when compared to monomeric J8
peptide given in CFA, and was also immunogenic when
delivered in the absence of adjuvant.
Fig.1. Chemical structure of the LCP-J8 construct. Four identical peptide J8 sequences were synthesised directly onto the two amino groups
of each lysine (Lys) of a branched polylysine core. The lipophilic anchor of the LCP-J8 construct contains three 2-amino-dodecanoic lipoamino
acids (shown as branched alkyl side chains) attached to the polylysine core, with a glycine amino acid spacer between the resin and the first
lipoamino acid, and a second between the second and third lipoamino acids.
Fig.2. Serum IgG antibody response in B10.BR mice immunized
parenterally with the LCP-J8 construct in the presence or absence of
CFA, for experiment 1 (A) and experiment 2 (B). Antibody titres to
the J8 peptide for individual mice are shown, with the average titre
(geometric mean) represented as a bar. Antibody titres to J8 are
shown for individual control mice that were immunized with J8 in
CFA. Antibody titres were significantly greater in mice immunized
with LCP-J8/CFA when compared to those immunized with J8 alone
in CFA (exp 1; *P<0.001). Significant differences in antibody titres
were also observed as indicated by **P<0.001, ***P<0.001 and
****P<0.001.
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Induction of opsonic antibodies in B10.BR mice
immunized with LCP-J8: Opsonic activity of serum IgG
antibodies elicited after parenteral delivery of LCP-J8
to the homologous M1 GAS strain was assessed
(Fig. 3). The average percentage opsonisation of M1
GAS by J8/CFA antisera generated in experiments 1
and 2 was 64 and 36 per cent, respectively, and the
pepM1 positive control gave an average percentage
opsonisation of 82 per cent for each experiment. The
average percentage opsonisation for LCP-J8/CFA
antisera against M1 was 71 per cent  (exp 1) and 68 per
cent  (exp 2); 64 per cent  (exp 1) and 76 per cent  (exp
2) for LCP-J8/PBS antisera. To confirm the specificity
of the opsonic antibodies induced in LCP-J8-immunized
mice, a peptide inhibition bactericidal assay was
performed. The opsonisation of M1 GAS by pooled
LCP-J8/CFA and LCP-J8/PBS antisera in the absence
of peptide was 37 and 55 per cent, respectively. Pre-
incubation of LCP-J8/CFA antisera with J8, however,
led to the complete inhibition of opsonisation. There was
a 91 per cent inhibition of opsonisation for LCP-J8/PBS
antisera pre-incubated with J8. The non-specific peptide
was shown to inhibit opsonisation of LCP-J8/CFA and
LCP-J8/PBS antisera by 12 and 27 per cent,
respectively. Incubation of pepM1 antisera with J8 also
had little effect on opsonisation (23% inhibition of
opsonisation), consistent with the fact that M protein
represents the amino terminal half of M protein.
The opsonic ability of LCP-J8 antisera against another
three GAS strains- NS27, 8830 and BSB24 was assessed
(Fig.3). LCP-J8/CFA and LCP-J8/PBS antisera opsonised
NS27 GAS with an average percentage opsonisation of 70
and 64 per cent,  respectively. Lower opsonisation was
Fig.3. Opsonisation of GAS by LCP-J8/CFA, LCP-J8/PBS and control (J8/CFA and pepM1/CFA) B10.BR mouse antisera for experiment
1 (A,C-E) and experiment 2 (B). The average percentage opsonisation for each individual group is shown with the standard error of the mean
represented as a bar. Opsonisation against M1 and BSB24 GAS was significantly greater in mice immunized with LCP-J8/CFA and LCP-
J8/PBS when compared to those immunized with J8 alone in CFA (exp 2, *P=0.051 and **P=0.008, respectively for M1; exp1, ***P=0.031
and ****P=0.013, respectively for BSB24).
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observed against 8830 GAS (27% for LCP-J8/CFA antisera
and 39% for LCP-J8/PBS antisera). In the case of BSB24,
LCP-J8/CFA and LCP-J8/PBS antisera opsonised GAS
with an average percentage opsonisation of 46 and 50 per
cent, respectively. J8/CFA antisera opsonised NS27, 8830
and BSB24 GAS with an average percentage opsonisation
of 40, 26 and 15 per cent, respectively. Antisera to pepM1
was shown not to opsonise the heterologous GAS strain,
BSB24.
Discussion
In this study we report on the synthesis,
immunogenicity and protective potential of a novel LCP-
GAS vaccine candidate incorporating a non-host cross-
reactive M protein conserved C-region protective peptide
epitope. Our data showed that mice immunized with the
LCP-J8 construct elicited high-titre serum J8-specific
IgG antibodies when the construct was coadministered
with CFA or administered alone. Further, opsonisation
of the homologous M1 GAS strain by LCP-J8/CFA and
LCP-J8/PBS antisera indicated that serum opsonic
antibodies were induced in mice following immunization
with the LCP-J8 construct. Moreover, the induction of
opsonic antibodies was not dependent on the presence
of conventional adjuvant, supporting the efficacy of the
LCP system as a self-adjuvanting GAS vaccine delivery
modality. The ability of the J8 peptide to inhibit the
opsonisation of M1 GAS by LCP-J8 antisera indicates
that LCP-J8 induced serum opsonic antibodies
specifically directed against the M protein conserved C-
region J8 peptide epitope on GAS, and that these
antibodies may potentially be important in protective
immunity against GAS.
This prompted us to determine whether serum IgG
antibodies induced to LCP-J8 could opsonise other GAS
strains, and secondly whether heart cross-reactive
antibodies were elicited. We assessed the opsonic ability
of the LCP-J8 antisera against another three GAS
strains- NS27, 8830 and BSB24. Both NS27 and 8830
contain an identical sequence to J8 in the C-region
whereas BSB24 has disparities in three amino acids
(underlined) with the sequence SREAKKKVEADL.
LCP-J8/CFA and LCP-J8/PBS antisera opsonised all
three GAS strains to varying degrees, with the highest
opsonisation observed against NS27. The induction of
serum heterologous opsonic antibodies against different
GAS strains following immunization of mice with LCP-
J8 was supportive of the efficacy of a broadly protective
GAS vaccine based on the conserved C-region of the
GAS M protein. Moreover, no cross-reactivity of LCP-
J8 antisera was observed to heart proteins in human heart
and mitral valve extracts. These data further highlighted
the potential of LCP-J8 in the induction of broadly
protective immune responses in the absence of
conventional adjuvant. These results supported our earlier
findings demonstrating the efficacy of the LCP system
as a vaccine delivery approach for enhancing the
immunogenicity of various synthetic peptide
immunogens23, 24, including viral and bacterially-derived
antigens.
In conclusion, the present findings indicated the
potential of the LCP system in the delivery of a self-
adjuvanting synthetic peptide GAS vaccine, with a view
to the development of a mucosal-based vaccine for
human application.
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